<div dir="ltr">segnalo questa notizia:<div><br></div><div><span style="color:rgb(31,31,31);font-family:"Google Sans",Roboto,RobotoDraft,Helvetica,Arial,sans-serif;font-size:22px;font-variant-ligatures:no-contextual">Kaerus Bioscience annuncia l'avvio di uno studio clinico di fase 1 per lo sviluppo del suo nuovo modulatore dei canali BK KER-0193 per la sindrome dell'X fragile</span><br></div><div><span style="color:rgb(31,31,31);font-family:"Google Sans",Roboto,RobotoDraft,Helvetica,Arial,sans-serif;font-size:22px;font-variant-ligatures:no-contextual"><br></span></div><div><a href="https://it.finance.yahoo.com/notizie/kaerus-bioscience-annuncia-lavvio-di-042900321.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAG4Kf7Vzf84n_uVMWQYLHLwa_LuULP_1UThnLUcedeLPZWbC4OYUd1G2gs6-cv6CSR2KqdJmAD0RNfrRwj3wha9CIMb7bXq4IB5ltIeWGoRXxh3S1b1jJWB8kkh0bvjK2r6f3ycDEmXdAPL888A1bS1gb3R_pkCYyhAjinBRKtfV">https://it.finance.yahoo.com/notizie/kaerus-bioscience-annuncia-lavvio-di-042900321.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAG4Kf7Vzf84n_uVMWQYLHLwa_LuULP_1UThnLUcedeLPZWbC4OYUd1G2gs6-cv6CSR2KqdJmAD0RNfrRwj3wha9CIMb7bXq4IB5ltIeWGoRXxh3S1b1jJWB8kkh0bvjK2r6f3ycDEmXdAPL888A1bS1gb3R_pkCYyhAjinBRKtfV</a> <span style="color:rgb(31,31,31);font-family:"Google Sans",Roboto,RobotoDraft,Helvetica,Arial,sans-serif;font-size:22px;font-variant-ligatures:no-contextual"><br></span></div><div><br></div><div><br></div></div>